Business Wire

Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel

Del

Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for axicabtagene ciloleucel as a treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) who are ineligible for autologous stem cell transplant. This application represents the first chimeric antigen receptor (CAR) T-cell therapy submitted to the EMA. Axicabtagene ciloleucel is currently under review by the U.S. Food and Drug Administration (FDA), and the FDA has set a Prescription Drug User Fee Act (PDUFA) action date of November 29, 2017.

The MAA for axicabtagene ciloleucel is supported by data from the ZUMA-1 trial, which met the primary endpoint of objective response rate (ORR), with 82 percent (p < 0.0001) of patients achieving a response after a single infusion of axicabtagene ciloleucel. At a median follow-up of 8.7 months, 44 percent of patients were in ongoing response, which included 39 percent of patients in complete response (CR). The most common Grade 3 or higher adverse events included cytokine release syndrome and neurologic events, which were generally reversible.

“The MAA submission of axicabtagene ciloleucel marks an important global milestone in the development of engineered T cell therapy,” said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. “We are excited to work closely with the EMA, Committee for Medicinal Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT) to help bring this potentially transformative therapy to patients in the EU.”

Non-Hodgkin lymphoma (NHL) is a type of blood cancer that affects around 93,000 people in Europe every year.i DLBCL is one of the subtypes of NHL that is aggressive or fast growing.ii While many patients can achieve and maintain complete remission after initial treatment, patients who experience relapse or do not respond to initial treatment historically have poor outcomes. The company estimates that approximately 7,800 patients in the EU 5 alone may benefit from CAR-T therapy.

In May 2016, the CHMP and CAT granted access to its newly established Priority Medicines (PRIME) regulatory initiative for axicabtagene ciloleucel in the treatment of patients with refractory DLBCL. Access to the PRIME initiative is granted by the EMA to support the development and accelerate the review of new therapies to treat patients with a high unmet need.

About axicabtagene ciloleucel

Kite's lead product candidate, axicabtagene ciloleucel, is an investigational therapy in which a patient's T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. Axicabtagene ciloleucel has been granted Breakthrough Therapy Designation status for diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) regulatory support for DLBCL in the EU.

About Kite

Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. Kite is based in Santa Monica, CA. For more information on Kite, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential of axicabtagene ciloleucel, and the ability to obtain EMA approval for axicabtagene ciloleucel. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-Q for the quarter ended March 31, 2017. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Kite assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

i Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer 2013;49:1374-1403.
ii Non-Hodgkin Lymphoma (NHL). “NHL Subtypes” Leukemia & Lymphoma Society. http://www.lls.org/lymphoma/non-hodgkin-lymphoma/diagnosis/nhl-subtypes [Last accessed July 20, 2017].

Contact information

Kite Contacts
Christine Cassiano
SVP, Corporate Communications & Investor Relations
ccassiano@kitepharma.com
Greg Mann
VP, Investor Relations
gmann@kitepharma.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

LINTEC Announces Four New Adhesive Materials for Labels20.9.2017 10:45Pressemelding

LINTEC Corporation (TOKYO: 7966) announced on September 20 that it will launch four newly developed label adhesive materials sequentially from October 2017. The new products will be on display prior to launch at Labelexpo Europe 2017, the world’s largest trade show in the label field. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005611/en/ LINTEC's super-strength adhesive labelstocks (Photo: Business Wire) Overview of Labelexpo Europe 2017 Date: September 25 (Mon.) to 28 (Thurs.) Venue: Brussels Expo, Belgium LINTEC Booth: Hall 3 3C 15 LINTEC Press Conference: 11:00 a.m. to 11:30 a.m., September 25, held in the Brussels Expo Press Office Theater Super-strength adhesive labelstocks: Extreme adhesion for rough surfaces Charac

EGS Invests in Artificial Intelligence from Quintiq20.9.2017 10:05Pressemelding

Quintiq, a Dassault Systèmes brand and global leader in supply chain planning and optimization (SCP&amp;O), announces that it has partnered with European Gateway Services (EGS) to bring a new level of intelligence to intermodal logistics. European Gateway Services (EGS) offers the market an integrated network for transport to and from the European hinterland. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005578/en/ EGS invests in artificial intelligence from Quintiq (Photo: Business Wire) To better support its customers, EGS takes standard planning strategies to a new level with a synchromodal trip optimizer using Quintiq’s planning and optimization software, which employs artificial intelligence to choose the optimal modes and routes at all times. Quintiq technology makes s

EchoStar 105/SES-11 Shipped from Toulouse to the Cape for SpaceX Launch20.9.2017 09:03Pressemelding

SES, EchoStar Corp., and Airbus Defence and Space announced today that the new EchoStar 105/SES-11 spacecraft, built by Airbus, has been shipped from the Airbus facilities in Toulouse, France, to Cape Canaveral, Florida, for its forthcoming launch by SpaceX in October. The first satellite that EchoStar has constructed with manufacturer Airbus, EchoStar 105/SES-11 will be launched by SpaceX on a flight-proven Falcon 9 rocket from Launch Complex 39A at Kennedy Space Center, Florida. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005539/en/ EchoStar 105/SES-11 Shipped from Toulouse to the Cape for SpaceX Launch (Photo: Business Wire) EchoStar 105/SES-11, a high-powered hybrid Ku and C-band communications satellite, is a dual-mission satellite for US-based operator EchoStar and Luxembourg-based

OT-Morpho Will Provide the Subscription Management Solution for Deutsche Telekom Group20.9.2017 08:41Pressemelding

OT-Morpho, a world leader in digital security and identification technologies, today announces that it has been selected by Deutsche Telekom AG (DTAG), a leading mobile network operator, to provide the first group wide subscription management solution, which has recently ensured the first commercial launch of a GSMA Phase 2 compliant consumer eSIM device in Germany and Croatia. DTAG’s choice relies on OT-Morpho’s highly innovative positioning and readiness on this technology and furthermore its engagement with major OEMs as a supplier of eSIMs. Indeed, OT-Morpho’s subscription management platform enables the secure download of the subscription into an eSIM, embedded or removable, already present in a device while ensuring the complete confidentiality and security of network data. OT-Morpho’s platform offers remote subscription provisioning services that are fully compliant w

Visa Announces Team Visa Roster for the Upcoming Olympic and Paralympic Winter Games20.9.2017 07:01Pressemelding

Visa (NYSE:V) today announced its global Team Visa roster for the Olympic and Paralympic Winter Games PyeongChang 2018, comprised of over 40 Olympians and Paralympians from 17 countries, including Mikaela Shiffrin (USA), Chloe Kim (USA), Mark McMorris (Canada), Gus Kenworthy (USA), Oksana Masters (USA), Lee, Sang Hwa (South Korea), Kamil Stoch (Poland), and Hilary Knight (USA). This team of Olympic and Paralympic hopefuls represent a diverse group of individuals representing a range of sports, from snowboarding and speed skating to ski jumping and figure skating. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005473/en/ Visa is excited to announce the #TeamVisa roster of athletes who are going for gold at #PyeongChang2018. (Photo: Business Wire) A global Olympic partner for more than 30 yea

Brooks Levitate with DNA AMP Delivers Infinite Energy20.9.2017 04:01Pressemelding

Based on seven years of Run Signature research, Brooks Running is launching the all new Levitate with DNA AMP—a shoe engineered to provide the most energy return of leading performance running shoes. The springy and responsive Brooks Levitate is available for pre-order beginning today at http://www.brooksrunning.com/en_us/brooks-levitate-running-shoes.html and will be available worldwide Sept. 30. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170919006747/en/ Brooks Levitate with DNA AMP Delivers Infinite Energy (Photo: Business Wire) “We’re pushing the limits of energy return with the new Brooks Levitate and are excited to unveil a shoe that has been engineered from the ground up to provide runners with an infinitely energetic experience,” said Carson Caprara, director of global product line ma

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom